News – Page 889 – Endpoints News

Christopher Haqq joins Elicio to hunt father's RAS cancer; Kronos expands top team with Gilead, Baylor vets

6 years ago

Provention Bio's diabetes drug gains PRIME status; Avrobio earns orphan status

6 years ago

AbbVie doubles down on cystic fibrosis R&D, adding a new drug to the pipeline as Vertex seals its domination of the ...

6 years ago

FDA revises guidance on postmarketing studies to reflect ARIA system, SUPPORT act

6 years ago

A tale of two IPOs (plus one): Cabaletta prices well below range for $75M while Phathom bags $182M

6 years ago

Novartis sends second wagon after KRAS gold rush

6 years ago

Gilead execs flag trial failures for Sjögren’s and lupus drugs — while swapping out a favorite HIV program of ...

6 years ago

FTC staff signs off on Roche $4.3B deal for Spark — report

6 years ago

Amgen commits to low-cost Repatha; AZTherapies bags Smith Therapeutics' CAR-Treg tech for neuroinflammation

6 years ago

Syros pushes for a turnaround with new PhII AML results, but investors are unimpressed

6 years ago

Impressing analysts with a big Q3, AstraZeneca whisks away the losers in the pipeline

6 years ago

Vertex finally makes NICE with England's NHS on CF therapies, but runs into hiccup with preclinical kidney drug data

6 years ago

Public funds help late-stage development of about 25% of new drugs, study finds

6 years ago

From $0 to $12B in an instant. Here's why biopharma loves risky Alzheimer's studies

6 years ago

Allievex launches with Pappas cash and rare disease drug from BioMarin

6 years ago

As clock ticks, Trump will nominate Stephen Hahn as FDA commissioner next week — report

6 years ago

Go big or go home: NIH, Bill and Melinda Gates Foundation join forces to make gene therapies affordable

6 years ago

GlaxoSmithKline celebrates another Zejula win in late-line ovarian cancer — and an FDA nod for the HRD biomarker

6 years ago

Acorda's Ron Cohen brings the ax back out as new drug sales only trickle in while cash cow is led to the slaughter

6 years ago

NeuroRx secures $95M to fund PhIII for NMDA depression drug; Trump revives science advisory council

6 years ago

RAPT Therapeutics returns to Wall Street to revive IPO bid

6 years ago

EY vet set to replace retiring Amgen CFO Meline

6 years ago

As shares suffer from a lingering slump, a bruised Alkermes slashes 160 jobs in R&D restructuring

6 years ago

Jean-Paul Clozel downplays recruitment delays holding up PhIII for Fabry disease

6 years ago

First page Previous page 886 887 888889890 891 892 Next page Last page